Drug Safety Concerns Create CRO Opportunity, PPD Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Contract research organizations could see financial opportunities in "more intricate safety monitoring," CEO Eshelman says during earnings call. Regulatory uncertainty accompanies shift in PPD's business away from big pharma, toward biotech firms.
You may also be interested in...
Takeda Broadens Diabetes Pipeline With PPD Agreement For DPP4 Inhibitors
Takeda completes acquisition of development and marketing rights to PPD’s dipeptidyl peptidase IV inhibitors for treatment of type 2 diabetes. PPD will provide clinical development services. The deal follows the discontinuation of Takeda’s in-house novel diabetes agent due to liver abnormalities.
Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: